News

Published on 28 Dec 2022 on Zacks via Yahoo Finance

After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc...


Article preview image

A downtrend has been apparent in Citius Pharmaceuticals, Inc. (CTXR) lately with too much selling pressure. The stock has declined 30.6% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.

Here is How to Spot Oversold Stocks

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

NASDAQ.CTXR price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Citius Pharma Reports 2024 Financial Results and Business Update

Citius Pharma ( (CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Cit...

TipRanks · via Yahoo Finance 30 Dec 2024

Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its...

Simply Wall St. · via Yahoo Finance 27 Dec 2024

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin...

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year Aft...

Benzinga · via Yahoo Finance 19 Aug 2024

Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

With the business potentially at an important milestone, we thought we'd take a closer look at Ci...

Simply Wall St. via Yahoo Finance 11 Feb 2024

Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its bus...

Simply Wall St. via Yahoo Finance 4 Sep 2023

Combination Therapy for Hemorrhoids: Citius' Combination Products Shows Meaningful Reduction In...

Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido, a topical treatment comprising lidocaine a...

Benzinga via Yahoo Finance 20 Jun 2023

When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its bus...

Simply Wall St. via Yahoo Finance 27 Mar 2023

After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc...

A downtrend has been apparent in Citius Pharmaceuticals, Inc. (CTXR) lately with too much selling...

Zacks via Yahoo Finance 28 Dec 2022

Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Ci...

Simply Wall St. via Yahoo Finance 18 Oct 2022

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

Citius Pharmaceuticals Inc (NASDAQ: CTXR) collaborated with the University of Pittsburgh for I/ON...

Benzinga via Yahoo Finance 22 Sep 2022